Prior to joining Nextech Invest in 2012, Dr Schroeder focused on research specializing on the development of novel cancer therapies in various roles at the University of Zurich, Switzerland, at Micromet Ltd. in Munich, Germany, (now Amgen) as well as during his studies at the University of Sydney, Australia. He holds a PhD in biochemistry from the University of Zurich, Switzerland, an MSc in biotechnology from the École de Supérieure de Biotechnologie de Strasbourg, France and a BSc in biology from the Technical University of Darmstadt, Germany. Dr Schroeder currently serves as board member of ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ: BPMC), SiROP Global, and prior board observer of Tracon Pharmaceuticals (NASDAQ: TCON).
Mr. Schroeder is responsible for the following Nextech portfolio companies:
Peloton Therapeutics, Kura Oncology, ImaginAb, Blueprint Medicines